期刊文献+

双能CT在乳腺癌中的应用进展

Application progress of dual-energy CT in breast cancer
下载PDF
导出
摘要 乳腺癌是女性最常见的恶性肿瘤,具有多种亚型及治疗方案,需早期诊断及分型。双能CT(DECT)通过使用2种不同能量水平的X射线实现物质的精确区分,经后处理生成的碘密度图可清晰显示乳腺癌病灶及内部导管扩张范围,同时生成多参数有助于乳腺癌的分子分型,以及转移、预后及疗效预测。就DECT在乳腺癌的应用现状及研究进展进行综述。 Breast cancer is the most common malignancy in women,with diverse subtypes and treatment options,making early diagnosis and classification critical.Dual-energy CT(DECT)enhances material differentiation by utilizing two distinct X-ray energy levels.The iodine density maps generated through post-processing provide clear visualization of breast cancer lesions and the extent of internal duct expansion.Additionally,DECT yields multiple parameters that aid in molecular typing,as well as in predicting metastasis,prognosis,and treatment efficacy for breast cancer.This article reviews the application and research progress of DECT in breast cancer.
作者 王子琪 赵文娟 靳玉尧 刘洋(审校) WANG Ziqi;ZHAO Wenjuan;JIN Yuyao;LIU Yang(Department of Radiology,Harbin Medical University Cancer Hospital,Harbin 150081,China)
出处 《国际医学放射学杂志》 2024年第6期707-711,共5页 International Journal of Medical Radiology
基金 黑龙江省博士后科研启动基金(LBH-Q20144) 黑龙江省卫生健康委科研课题(20230909010242)。
关键词 双能CT 乳腺癌 虚拟单能谱影像 分子分型 Dual energy CT Breast cancer Virtual monoenergetic imaging Molecular type
  • 相关文献

参考文献11

二级参考文献153

  • 1祁琦,徐菁,恽蓓,李军.乳腺癌中Ki-67表达与微血管密度和微淋巴管密度的相关性[J].中国肿瘤临床与康复,2020,0(3):344-347. 被引量:18
  • 2东强,曲丽洁,张宏,余玉盛,郭溪,徐青.双能量CT碘值及增强值与进展期胃腺癌病理分化程度的相关性[J].临床放射学杂志,2020,39(5):931-935. 被引量:18
  • 3中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2007版)[J].中国癌症杂志,2007,17(5):410-428. 被引量:234
  • 4Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifcn to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trim [J]. Lancet, 2013, 381(9869): 805-816.
  • 5Gray RG, Rea D, Handley K, et al. aTl'om: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6935 women with early breast cancer [ EB/OL ]. [ 2016-02-03 ]. http ://meetinglibrary. asco. org/content/112995-132.
  • 6LHRH-agonists in Early Breast Cancer Overview group, Cuzick J, Ambroisine L, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone- receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trims [ J ]. Lancet, 2007, 369 (9574) : 1711-1723.
  • 7Gnant M, Mlineritsch B, Stoeger H, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopansal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial [ J ]. Lancet Oncol, 2011, 12(7) : 631-641.
  • 8Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer [ J ]. N Engl J Med, 2014, 371(2) : 107-118.
  • 9Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopansal hormone-receptor-positive advanced breast cancer [ J ]. N Engl J Med, 2012, 366(6) : 520-529.
  • 10Robertson JF, Llombart-Cussac A, Rolski J, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study I J]. J Clin Oneol, 2009, 27(27): 4530-4535,.

共引文献423

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部